The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Ryan Richardson joined BioNTech in 2018 and has served as Chief Strategy Officer since January 2020. During his time at the Company, he contributed significantly to BioNTech’s successful development, ...

The U.S. Food and Drug Administration's panel of independent advisers voted on Thursday against approval of GSK's blood ...

This new Shingrix vaccine presentation eliminates the need for reconstitution, simplifying the administration process for ...

GSK Plc’s blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting its approval in doubt.

Treatments for bronchiectasis, chronic immune thrombocytopenia, fibromyalgia, Friedreich ataxia, and recurrent respiratory papillomatosis are under review.

Johnson & Johnson (JNJ) gets FDA priority review for TAR-200 gains, a drug releasing system targeting bladder cancer. Read ...

Following in the footsteps of other pharmaceutical companies, Bristol Myers Squibb and Pfizer are offering Eliquis for cash-paying patients at a discount of 40% off the list price.

The American Academy of Dermatology has updated its guidelines for treating and managing atopic dermatitis with topical and ...

As Boston Scientific gears up for its upcoming earnings release on July 23, the market is ripe with anticipation. Analysts, armed with revised forecasts, project a robust year-over-year increase in ...